Literature DB >> 24343665

Haematological cancer: Deep molecular response predicts survival in CML.

Mina Razzak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24343665     DOI： 10.1038/nrclinonc.2013.235

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Authors:  Rüdiger Hehlmann; Martin C Müller; Michael Lauseker; Benjamin Hanfstein; Alice Fabarius; Annette Schreiber; Ulrike Proetel; Nadine Pletsch; Markus Pfirrmann; Claudia Haferlach; Susanne Schnittger; Hermann Einsele; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Gerhard Ehninger; Dominik Heim; Hermann Heimpel; Christoph Nerl; Stefan W Krause; Dieter K Hossfeld; Hans-Jochem Kolb; Joerg Hasford; Susanne Saußele; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544
  1 in total
  1 in total

1.  Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia.

Authors:  Z Chen; L J Medeiros; H M Kantajian; L Zheng; Z Gong; K P Patel; H Xiong; W Wang; J E Cortes; S Hu
Journal:  Blood Cancer J       Date:  2017-02-03       Impact factor: 11.037
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.